Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva gets FDA nod to begin phase 2 trial to treat diabetes/liver disease
10:21am, Tuesday, 08'th Mar 2022 Seeking Alpha
Inventiva (IVA) said the U.S. Food and Drug Administration ((FDA)) concluded that a phase 2 trial of the company''s drug lanifibranor in combination empagliflozin to treat patients…
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
07:00am, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
09:27pm, Monday, 07'th Mar 2022 GlobeNewswire Inc.
Initiation of the NATiV3 Phase III clinical trial with lanifibranor in NASH Receipt of a €4 m milestone payment from AbbVie following the inclusion of the first patient in the ongoing Phase IIb c
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
09:27pm, Monday, 07'th Mar 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 7 mars 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de peti
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis
09:00pm, Monday, 07'th Mar 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 7 mars 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de peti
Inventiva annonce sa participation à plusieurs conférences investisseurs en mars 2022
09:00pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 1er mars 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de pe
Inventiva announces participation at several conferences in March 2022
09:00pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), March 1, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
09:00pm, Monday, 28'th Feb 2022 GlobeNewswire
Daix (France), Long Island City (New York, United States), February 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s full-year financial results for 2021 on Tuesday, March 8, 2022.
Wall Street Analysts Think Inventiva S.A. Sponsored ADR (IVA) Could Surge 153%: Read This Before Placing a Bet
03:00pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
The consensus price target hints at a 152.7% upside potential for Inventiva S.A. Sponsored ADR (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend
Inventiva publie sa position de trésorerie et son chiffre d’affaires pour l’exercice 2021
09:00pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 14 février 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de
Inventiva reports cash position and revenues for Full-Year 2021
09:00pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), February 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of or
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
01:28pm, Tuesday, 01'st Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
ImmunityBio Announces Positive Phase 1 Data For Anktiva In HIV
ImmunityBio, Inc. (NASDAQ: IBRX) announ
Inventiva gets 4M milestone payment from AbbVie in cedirogant trial to treat psoriasis
09:09pm, Monday, 31'st Jan 2022 Seeking Alpha
Inventiva (IVA) received a 4M milestone payment from AbbVie (ABBV) following the inclusion of the first patient with psoriasis in an ongoing phase 2b trial with
Inventiva reçoit un paiement d'étape de 4 M€ de la part d’AbbVie suite au lancement de l’étude de Phase IIb avec cedirogant
09:00pm, Monday, 31'st Jan 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York), Etats-Unis, le 31 janvier 2022 – Inventiva S.A. (« Inventiva » ou la « Société ») (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spé
